WEgovy Real World Assessment of Weight Loss in Korea

WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Study Overview

• Status: Enrolling by invitation
• Conditions: Obesity
• Intervention / Treatment: Drug: Semaglutide

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

Study Locations

• South Korea
  • Daejeon, South Korea, 35220
    • Daejeon Endo Internal Medicine Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

Description

Inclusion Criteria:

1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
3. Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
4. Male or female, aged ≥ 19 years at the time of signing the informed consent.

Exclusion Criteria:

1. Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
2. Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Once weekly Wegovy; Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.	Drug: Semaglutide; Semaglutide injection will be self-administered once weekly subcutaneously.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage change in body weight	Percent (%)	From baseline (week 0) to 24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute change in body weight	Kilogram (kg)	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percentage change in body weight	Percent (%)	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction more than or equal to (≥) 5%	Count of patients	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 10%	Count of patients	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 15%	Count of patients	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 20%	Count of patients	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass	Kg	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass	Kg	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass	Percent (%)	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass	Percent (%)	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in Body mass index (BMI)	Kilogram per meter square (kg/m^2)	From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2)	Count of patients	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class II obesity (30 to 34.9 kg/m^2)	Count of patients	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class III obesity (≥35 kg/m^2)	Count of patients	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in waist circumference	Centimetre (cm)	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Systolic blood pressure (SBP)	Millimetres of mercury (mmHg)	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Diastolic blood pressure (DBP)	mmHg	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Fasting plasma glucose (FPG)	Milligram per deciliter (mg/dL)	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Haemoglobin A1c (HbA1c)	Percent (%)	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: total cholesterol (TCh)	mg/dL	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: high-density lipoprotein cholesterol (HDL-C)	mg/dL	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: low-density lipoprotein cholesterol (LDL-C)	mg/dL	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: triglycerides (TG)	mg/dL	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: free fatty acid (FFA)	mg/dL	From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in status of type two diabetes mellitus (T2DM)	Count of patients	Baseline (week 0) to 52 weeks [or end of the study (EOS)]
Change in status of Hypertension	Count of patients	Baseline (week 0) to 52 weeks (or EOS)
Change in status of Dyslipidemia	Count of patients	Baseline (week 0) to 52 weeks (or EOS)
Number of treatment-emergent adverse events (TEAEs)	Count of events	From baseline (week 0) to 52 weeks (or EOS)
Number of serious TEAEs	Count of events	From baseline (week 0) to 52 weeks (or EOS)

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S
• Investigators: Study Director: Clinical Transparency dept. 2834, Novo Nordisk A/S

Study record dates

Study Major Dates

• Study Start (Actual): November 10, 2025
• Primary Completion (Estimated): October 31, 2027
• Study Completion (Estimated): October 31, 2027

Study Registration Dates

• First Submitted: November 24, 2025
• First Submitted That Met QC Criteria: December 10, 2025
• First Posted (Actual): December 12, 2025

Study Record Updates

• Last Update Posted (Actual): December 12, 2025
• Last Update Submitted That Met QC Criteria: December 10, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Body Weight; Overweight; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity; semaglutide
• Other Study ID Numbers: NN9536-7850; U1111-1306-1595 (Other Identifier: WHO)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com